Search results: (10000)
News HAE and its Management in Pediatric Patients
Hereditary angioedema (HAE) can be encountered in the emergency room as well as in specialist practices. Patients with this rare disease are often incorrectly diagnosed with other, more common conditions, and it can take many years before they receive the correct diagnosis. This is because the symptoms of HAE overlap with those of other illnesses. What should pediatricians, otolaryngologists, and gastroenterologists be aware of? To provide a better understanding of HAE symptoms from the perspective of various specialties and emphasize the importance of interdisciplinary collaboration for the correct diagnosis and care of patients with HAE, a professional webinar was held. We have prepared a summary of the most important points for you.
News Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study
In a case study involving a 78-year-old diabetic patient, where only the administration of empagliflozin led to the correction of severe anemia of unknown origin, Polish authors demonstrate the previously described pleiotropic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) on increasing hematocrit levels.
News Heart Failure in Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd at 5 PM.
You can find more information in the attached invitation below.
You can find more information in the attached invitation below.
News Impact of Primary Tumor Location and Early Regression on Survival in Patients with Metastatic CRC
Results from recent clinical studies suggest the prognostic significance of the primary tumor location on the survival of patients with metastatic colorectal cancer (mCRC). A retrospective analysis of data from a single-arm open-label phase II clinical trial evaluated the impact of primary tumor location and its early regression (ETS - early tumor shrinkage) on the survival of patients with mCRC who received a combination of chemotherapy (FOLFIRI regimen) and targeted biological therapy (panitumumab).
News Romiplostim in Routine Clinical Use among Patients with ITP in European Countries − Fresh Data Analysis
Data from randomized clinical trials have shown that romiplostim is an effective medication for many patients not only with acute or persistent immune thrombocytopenia (ITP) but also for much more complicated patients with chronic ITP. In April 2021, data on the efficacy and safety of romiplostim from European clinical practice were published.
News N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up
An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
News Risk Factors for Renal Cancer Formation After Kidney Transplantation
German authors in the below-cited work identified modifiable risk factors associated with the development of renal cell carcinoma (RCC) de novo in patients after kidney transplantation.
News Incidence of Glaucoma or Suspected Glaucoma Within the First Year Post-Lensectomy in Children and Treatment Approach to These Patients
The aim of the study conducted by a team of authors from several American universities was to determine the approximate incidence of glaucoma or suspected glaucoma in children under 13 years old within the first year after lensectomy and to describe the management of care for these patients.
News Romiplostim in ITP Treatment – Data from German Clinical Practice
Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and chronic.
News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency
The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.
News Levothyroxine Substitution Depending on Patient Genotype
Careful titration of hormone dose leads to optimal dosing of replacement therapy for hypothyroidism. The authors of a cross-sectional study published in the Endocrine Journal examined the impact of polymorphisms in genes for proteins involved in thyroid hormone metabolism on the response to levothyroxine treatment in patients after thyroidectomy.
News Initiation of Sacubitril/Valsartan After Acute Decompensation of Chronic Heart Failure: The Sooner, the Better
The recently published analysis of data from the extended open-label follow-up of participants in the PIONEER-HF study clearly pointed out the difference in outcomes and prognosis of patients, which is led by the initiation of the combined drug during hospitalization compared to its initiation shortly after discharge.
News Socio-economic Benefits of Using Obinutuzumab in 1st Line Treatment of Follicular Lymphoma
Pharmacoeconomic analyses remind us that our patients' diseases affect not only themselves or the healthcare system, but also have an impact on the entire society. Patients with follicular lymphoma (FL) are also life partners, parents, relatives, and household members, and last but not least, they are also employees or service workers. How treatment success can reflect in these aspects is suggested by a German study.
News Recommended and Not Recommended Physical Activity for Individuals with Hemophilia
Physical activity is now considered a fundamental prerequisite for maintaining the health of individuals with hemophilia. The World Federation of Hemophilia (WFH) also recommends it to improve fitness and neuromuscular health. Numerous studies have shown that physical activity can help enhance the effectiveness of hemophilia treatment and prevent bleeding episodes. In older individuals, including those with hemophilia, a lack of physical activity increases the risk of developing diabetes, hypertension, dyslipidemia, obesity, and osteoporosis, along with subsequent fractures and complications associated with hemophilia.
News Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis
Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on structural lesions in patients with early forms of axial spondyloarthritis (AxSpA). The aim of the study presented below, published in January 2021, was to evaluate structural changes in the sacroiliac joint (SIJ) on magnetic resonance imaging (MRI) after 2 years of treatment with etanercept within the clinical study EMBARK in patients with early AxSpA compared to a control cohort not treated with biologics (DESIR) and to assess the relationship between MRI changes and disease activity according to ASDAS.
News Long-term results of alpha-1-antitrypsin deficiency treatment – RAPID program
RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of alpha-1-antitrypsin inhibitor in the treatment of chronic obstructive pulmonary disease (COPD) associated with its deficiency.
News Sport and Physical Activity Benefit Hemophiliacs
Sport and physical activity are beneficial for individuals with hemophilia. This statement was confirmed by a study conducted by German and British authors published in the journal Haemophilia.
News Efficacy of Romiplostim in Children with Persistent or Chronic ITP
The effect of the thrombopoietin receptor agonist romiplostim in adult patients with immune thrombocytopenia (ITP) is well known. Equally important, however, are data on its treatment in children — presented by a study whose results were published in the journal Lancet.
News Genetic Testing in Non-Small Cell Lung Cancer - Clinical Practice Experience
Targeted therapy has brought significant improvements to certain groups of patients with non-small cell lung cancer (NSCLC). Selecting patients who will benefit from targeted therapy can be performed using molecular profiling with next-generation sequencing (NGS) techniques. However, we still lack sufficient data on the feasibility and results of such profiling in real-world clinical practice, which was the focus of an analysis recently published in The Oncologist.
News Comparison of the effects of fibrinogen concentrates and fresh frozen plasma in patients with acute traumatic coagulopathy
A quasi-experimental study compared the effectiveness of fibrinogen concentrates and fresh frozen plasma in patients with severe blunt trauma requiring the administration of erythrocyte replacements.
News The role of the physiotherapist in hemophilia care is expanding and irreplaceable − what it entails and how it changes with treatment advances?
In the team cooperation in caring for patients with hemophilia, the physiotherapist plays a very important role, which is expanding with today's comprehensive approach to treating this condition. The reason is that even in the era of modern treatment availability, many hemophilia patients have various musculoskeletal complications. A team of authors, preferentially physiotherapists, recently published a paper pondering whether the advent of new drugs will also change the position of physiotherapy in the care of patients with hemophilia.
News Manual Fascial Therapy in Patients with Hemophilic Arthropathy
Fascial therapy is a rehabilitative technique that mobilizes the fascial complex using manual techniques with the goal of improving tissue mobility and function, as well as influencing pain. A team of experts from Spain evaluated the safety of this method in hemophiliacs with developed arthropathy in their study.
News Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum FVIII levels > 1%. However, it has been shown that this goal may not protect many hemophiliacs from bleeding episodes. So how does prophylaxis that maintains higher FVIII levels stand? These insights were brought by the PROPEL study, whose results were recently published in Blood magazine.